(3E,5E,11E,13E)-16-[4-(2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl)-3-hydroxypentan-2-yl]-8-hydroxy-15-methoxy-3,5,7,9,11-pentamethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: (3E,5E,11E,13E)-16-[4-(2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl)-3-hydroxypentan-2-yl]-8-hydroxy-15-methoxy-3,5,7,9,11-pentamethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
• 化学式: C₃₅H₅₈O₈
• 分子量: 606.8
• InChiKey: RZJZXSWAZNJLMG-CNXVTWNFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  43
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• COMPOSITIONS OF A V-ATPASE INHIBITOR IN COMBINATION WITH A GLUCOCORTICOID RECEPTOR LIGAND AND METHODS OF USE
  申请人：XU HUAQIANG ERIC

  公开号：US20110237497A1

  公开（公告）日：2011-09-29

  A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having an inflammatory or auto-immune disease by administering such composition.